Defence Therapeutics: Developing Next Generation Biopharmaceutical Innovations

October 26, 2022

Stocks to Invest in: Healthcare

Defence Therapeutics is a publicly-traded biotechnology company working on engineering the next generation vaccines and ADC products using its proprietary platform. The core of Defence Therapeutics platform is the ACCUM technology, which enables precision delivery of vaccine antigens or ADCs in their intact form to target cell.

Defence Therapeutics is a Canadian Biotech developing next generation biopharmaceutical innovations for various immuno-oncology (IO) and infectiousdiseases (ID) indications

For more information on Defence Therapeutics Inc. (CSE: DTC, OTC: DTCFF) please click the request investor info button.


You might also like

Healthcare
Lexaria Bioscience: Revolutionizing GLP-1 Drug Delivery with Patented Oral Platform

Lexaria Bioscience is setting new standards in drug delivery with its patented DehydraTECH™ oral technology, optimizing absorption for GLP-1 and other high-demand drugs.

Healthcare
Lexaria Bioscience: Advancing GLP-1 Drug Delivery with DehydraTECH™ Technology

Lexaria Bioscience’s DehydraTECH™ technology aims to redefine oral drug delivery, focusing on faster absorption and improved efficacy, with a promising impact on the GLP-1 pharmaceutical market.

Content Broadcast on: BNN Bloomberg, CNBC, Bloomberg, FOX Business News, BIZTV, Reuters, The Globe and Mail, YouTube and more!